Ufovax holds exclusive rights to develop and commercialize vaccines using this patented technology.
Publication entitled “Proof of concept forrational design of hepatitis C virus E2 core nanoparticle vaccines” in Science Advances.
Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are responsible for cell entry, with E2 being the major target of neutralizing antibodies (NAbs). Here, we present a comprehensive strategy for B cell–based HCV vaccine development through E2 optimization and nanoparticle display. We redesigned variable… [Read more]